Fundz

AL-S Pharma Appoints Harry Welten as Chief Executive Officer

PRIVATEOct 14, 2026

Position

Chief Executive Officer

Company

AL-S Pharma AG

Harry Welten
ZurichBiotechnologyHealth CareTherapeuticsPharmaceutical

Description

AL-S Pharma AG announced the appointment of Harry Welten as chief executive officer (CEO). He succeeds Michael Salzmann, Ph.D.

Quick answer

AL-S Pharma Appoints Harry Welten as Chief Executive Officer (October 14, 2026). AL-S Pharma AG is based in Zurich, Zurich, Switzerland.

Who is the new Chief Executive Officer at AL-S Pharma AG?
AL-S Pharma AG named Harry Welten Chief Executive Officer, announced October 14, 2026.
What did AL-S Pharma AG announce on October 14, 2026?
AL-S Pharma AG announced the appointment of Harry Welten as chief executive officer (CEO).
What does AL-S Pharma AG do?
AL-S Pharma is a Swiss-based single-asset company focused on developing AP-101 for treating amyotrophic lateral sclerosis (ALS).
Where is AL-S Pharma AG based?
AL-S Pharma AG is based in Zurich, Zurich, Switzerland.
Which similar companies made leadership changes around the same time?
TORL BioTherapeutics (October 16, 2026), Jazz Pharmaceuticals plc (October 9, 2026), Retension Pharmaceuticals (October 23, 2026) and Acadia Pharmaceuticals (October 23, 2026) also announced leadership changes within 45 days of AL-S Pharma AG.

Source: Fundz verified event record.

Other recent leadership changes in Therapeutics and Pharmaceutical

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at AL-S Pharma AG, and when

A new leader at AL-S Pharma AG brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day AL-S Pharma AG raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at AL-S Pharma AG, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at AL-S Pharma AG. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

AL-S Pharma AG

Location

Zurich, Zurich, Switzerland

About

AL-S Pharma is a Swiss-based single-asset company focused on developing AP-101 for treating amyotrophic lateral sclerosis (ALS). It was co-created by Neurimmune and TVM Capital Life Science. The company leverages a network of ALS experts to execute its innovative clinical plans. AL-S Pharma is committed to advancing the clinical development of therapies targeting misfolded SOD1.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment AL-S Pharma AG changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for AL-S Pharma AG's next move

Learn about Strategic plan

AL-S Pharma AG changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.